Behringwerke Aktiengesellschaft

Thomas Stief

Norbert Heimburger

Hans U Schorlemmer

Klaus-Peter Radtke

A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Transglutaminases as immunosuppressants

The disclosed invention provides a method for determining the plasminogen activator (PA) activity in a biological fluid. The method involves the use of proteolytically-degraded plasminogen and effectively eliminates the influence of alpha-2-antiplasmin on the determination of PA activity.

Method for the determination of the plasminogen activator activity in

A method and an agent for the functional determination of protein C inhibitor in body fluids are described, in which this fluid is incubated with a known amount of a plasminogen activator, fibrinogen and a sulfated carbohydrate, and the residual activity of the plasminogen activator is determined, and from this the amount of protein C inhibitor is determined.

Method for the functional determination of protein C inhibitor

Use of transglutaminases as immunosuppressants

Oxidized derivatives of-fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.

Fibrin(ogen) derivatives, process for their preparation and their use

Oxidized derivatives of fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.

The invention relates to a method for the determination of the activity of serine proteases and serine protease inhibitors in plasma or other biological fluids. The only methods hitherto available for rapid and accurate determination of the content of serine proteases or serine protease inhibitors have been very time-consuming and methodologically demanding. In the method according to the invention for the determination of the activity of serine proteases or serine protease inhibitors, specific inhibitors are inactivated by addition of at least one oxidizing agent and, where appropriate, at least one detergent. The addition of an omega-aminocarboxylic acid enhances and observed effects when the serine protease is plasmin.

Growing community of inventors

Sevilla, Spain

Thomas Stief